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Ebola virus disease and 
palliative care in 
humanitarian crises
DR Congo is currently facing its tenth 
outbreak of Ebola virus disease (EVD) 
since the virus was discovered in 
1976. As of March 3, 2019, there were 
897 confirmed cases, with 563 deaths 
(including confirmed and probable 
deaths).1 Although potentially 
effective ring vaccination trials have 
been integrated into the response 
against EVD, the risk of further 
propagation of the outbreak remains 
high. The virus has spread to densely 
populated urban areas, and parts of 
the country where optimal surveillance 
and health­care delivery are dangerous 
and sometimes interrupted due to the 
presence of armed groups.
Since the mortality in individuals 
with EVD is high (around 50%)2,3 
and no effective pharmacological 
treatments have been identified, many 
patients with EVD will die, even in the 
best circumstances. In October, 2017, 
the Lancet Commission on palliative 
care4 pointed out that palliative care 
has been largely ignored, especially for 
the most vulnerable populations and 
those living in humanitarian crises. 
In The Lancet, François Lamontagne 
and colleagues5 highlighted just how 
entrenched the problem is.
Although Lamontagne and col­
leagues’ guidelines stress the impor­
tance of supportive and psychosocial 
care to alleviate the burden of suffering 
and severe distress associated with EVD, 
these guidelines do not acknowledge 
the value of this care for all patients 
regardless of outcome, even death. 
This is consistent with other published 
recommendations for EVD patient 
management.5,6
The value of these guidelines 
is clear: to facilitate faster and 
more standardised care informed 
by a synthesis of existing (albeit 
limited) evidence on what is most 
likely to help patients affected by 
EVD. Nevertheless, until curative 
treatments for the management of 
EVD are available, clinical guidelines 
and specific protocols for EVD 
must include clear recommendations 
and instructions on the integration 
of palliative care into the delivery 
of optimum care for patients with 
suspected and confirmed EVD.
Guidelines on palliative care for 
EVD need to be clearly defined so 
that its value and place in high­
fatality humanitarian crises can 
begin to gain practical traction 
and acceptability. Clearly defined 
guidelines on palliative care would 
also legitimise training and dialogue 
on palliative care in contexts where 
staff have no previous experience 
treating patients with EVD.6
Palliative care and pain relief are 
essential elements of universal health 
coverage,4 but much more should be 
done to make it part of any health 
intervention. A first step is to ensure 
that health professionals, patients, 
and families understand that palliative 
care can improve patient quality of life 
and prevent and alleviate suffering. 
Ensuring that palliative care gets 
explicitly integrated into guidelines 
for care of critically ill people, including 
but not limited to patients with EVD, is 
of equal importance.
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